arrow
R

Rodrigo A. Toledo

vall d’hebron institute of oncology
H指数:35
被引数:4,418

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identifying TMEM127-deficient pheochromocytomas/paragangliomas via RET overexpression by immunohistochemistry

通过免疫组化检测RET过表达以识别TMEM127缺陷型嗜铬细胞瘤/副神经节瘤

2026-07-170
PRE
Reference materials and external quality assessment for liquid biopsy assays: Expert opinions from the European Liquid Biopsy Society ctDNA workshop

液体活检检测的参考材料和外部质量评估:欧洲液体活检学会ctDNA研讨会专家意见

2026-01-010
OAAI
Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI

通过基于组织学信息的在体扩散MRI进行临床可行的肝脏肿瘤细胞尺寸测量

2025-11-200
OAAI
Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRI
2024-06-190
OA
Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology

无细胞DNA片段谱中的细胞类型特征揭示了疾病生物学

2024-03-129
OAAI
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

血浆BRAF-V600E等位基因分数作为BRAF组合治疗转移性结直肠癌的预后因素

2023-06-0136
OA
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

RNF43突变预测BRAFV600E转移性结直肠癌对抗BRAF/EGFR联合治疗的反应

2022-09-1263
OAAI
International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma
2021-08-278
OAAI
Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR plus /- MEK inhibitors
2021-07-019
OAAI
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
2018-07-3127
OAAI